Export Markets Sample Clauses

Export Markets. The Company may procure that its Subsidiaries market, sell and distribute throughout the Export Markets any Xxxxxxx Juices and such other beverage or snack foods as the Board may approve from time to time, provided that neither the Company nor its Subsidiaries, without the prior consent of PepsiCo, shall engage in the manufacture of the Xxxxxxx Juices in the Export Markets nor procure such manufacture by a third party nor license any third party to manufacture the Xxxxxxx Juices in the Export Markets. PAS hereby acknowledges PepsiCo’s right (either directly or through its Affiliates or through third parties) to engage independently of the Company in the manufacture, sale and distribution of juices and juice based beverages (other than the Xxxxxxx Juices) throughout the Export Markets.
Sample 1
AutoNDA by SimpleDocs
Export Markets. According to fresh fruit exporters, profit margins in export of fresh apricots are significantly higher than those in traditionally exported fruits like mangoes and citrus. Currently, all fresh apricots being exported are first imported from Afghanistan, repackaged and then exported to the Middle East. Exporters in Karachi had indicated that their ability to export apricots is limited mainly by the quantities available from Afghanistan (Apex Consulting Study 2010). A few traders in Gilgit assert that apricots from Gilgit Baltistan can be exported to by air through Skardu airport. They state that there is at least one daily PIA flight between Skardu and Islamabad (subject to weather conditions). This flight can be used to fly batches of pre-packed fresh apricots to Islamabad that can then be flown to a number of Middle Eastern and European destinations through a number of direct flights. Huge figures were reported in an earlier study done on commercial potential of apricots from the Gilgit Baltistan region. Potential sales were assumed on the basis of the total estimated production of the entire region. During the validation process, this consultant however understood that several practical limitations on grounds mentioned above would make it impossible to realize volumes as projected in the earlier studies. A more pragmatic estimate by the consultant is given below in Table 12 for an estimated projection.
Sample 1
Export Markets. World fresh apricot trade stood at slightly above USD 440 million in the year 2012. A total of 323 thousand tons were exported at an average price of USD 1,363 per ton. Dried apricot trade stood at US dollar 391 million in 2012, with a total of 164,400 tons exported at an average price of USD 2380 per ton. The largest volumes of apricot exports were traded fresh (53.6%) followed by 27.3% of dried apricot traded internationally. Apricot processed product exports were 19.1% of total volumes traded. Fresh apricot international trade steadily increased 21% annually between 2008 and 2012, whereas dried and processed apricot international trade remained static in those five years. ITC Statistics indicate that there is a sizeable (USD 157 million) international market for apricot products. International trade of processed apricots comprised 16% of world trade in terms of value ,and 19% of trade volume in 2012. It is worth noting that Pakistan was not present in the processed apricot products category. It is also worth noting the comparison in Table 15 below, while fresh apricot exports were a bigger portion of world trade, Pakistan’s fresh trade lagged behind dried apricot exports both in value and volume. The table below shows the product mix of world apricot markets, and Pakistan’s share of mthe arket in the respective categories. Table 15: World Apricot Trade Product Mix Comparison in 2012 World Apricot Trade: Product Mix 000 USD Tons Value % Qty % Fresh 440,163 323,022 44.5% 53.6% Dried 391,323 164,400 39.6% 27.3% Processed 157,561 114,912 15.9% 19.1% Total 989,047 602,334 100% 100.0% Pakistan Apricot Trade: Product Mix 000 USD Tons Value % Qty % Fresh 438 396 30.6% 48.5% Dried 993 420 69.4% 51.5% Processed - - - - Total 1,431 816 100% 100% Source: Authors Calculations based on ITC Trade Map Statistics Chart 6: World Apricot Trade Mix ($ Value) Source: ITC Trade Map Statistics Chart 7: World Apricot Trade Mix (Volume) Source: ITC Trade Map Statistics World Trade: Fresh Apricots The majority of apricots are consumed in producing countries, and approximately only 8% of world production was traded in 2012 (ITC and FAO Stats). As mentioned earlier, total world trade of fresh apricots stood at slightly above USD 440 million in the year 2012 (apricots, fresh defined under Harmonized code 080910). The volume of trade stood at 323 thousand tons in 2012. In the world markets, the largest volumes of apricot exports are traded fresh. Fresh apricot exports have steadily ...
Sample 1

Related to Export Markets

  • Joint Marketing After receiving Xxxxxxxx’s advance written approval, which will not be unreasonably withheld, SHIFT4 may list and announce Merchant as a user of SHIFT4’s service, but will make public announcements of Merchant’s use or describe Xxxxxxxx’s use of service only for marketing purposes.

  • Export Control This Agreement is made subject to any restrictions concerning the export of products or technical information from the United States or other countries that may be imposed on the Parties from time to time. Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate agency or other governmental entity in accordance with Applicable Law.

  • Export Administration Each party agrees to comply with all export laws and regulations of the United States (“Export Laws”) to assure that no software deliverable, item, service, technical data or any direct product thereof arising out of or related to this Agreement is exported directly or indirectly (as a physical export or a deemed export) in violation of Export Laws.

  • Exports Each Party agrees not to export or re-export, directly or indirectly, any information, technical data, the direct product of such data, samples or equipment received or generated under this Agreement in violation of any applicable export control Laws.

  • DIRECT MARKETING Prior to the introduction of any new product or service which Competitive Supplier may wish to make available to Participating Consumers or other Eligible Consumers located within the Town, Competitive Supplier agrees to (i) give the Town written notice of such new product or service and (ii) subject to the entry into reasonable confidentiality terms to the extent permitted by law and mutually acceptable to the Parties, discuss with the Town the possible inclusion of such new product or service in this aggregation program. The Parties agree to negotiate in good faith the terms, conditions, and prices for such products and services which the Parties agree should be included in a Town aggregation program. Competitive Supplier also agrees not to engage in any direct marketing to any Participating Consumer that relies upon Competitive Supplier’s unique knowledge of, or access to, Participating Consumers gained as a result of this ESA. For the purposes of this provision, “direct marketing” shall include any telephone call, mailing, electronic mail, or other contact between the Competitive Supplier and the Consumer. Broad-based programs of the Competitive Supplier that do not rely on unique knowledge or access gained through this ESA will not constitute such “direct marketing.”

  • Export 12.1 Export laws and regulations of the United States and any other relevant local export laws and regulations apply to the Services. Such export laws govern use of the Services (including technical data) and any Services deliverables provided under this Agreement, and You and we each agree to comply with all such export laws and regulations (including “deemed export” and “deemed re-export” regulations). You agree that no data, information, software programs and/or materials resulting from the Services (or direct product thereof) will be exported, directly or indirectly, in violation of these laws, or will be used for any purpose prohibited by these laws including, without limitation, nuclear, chemical, or biological weapons proliferation, or development of missile technology.

  • Market Orders are executed immediately at the best available price in the system.

  • Regulatory Authorities Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and its subsidiaries: (i) are in compliance in all material respects with all statutes, rules, regulations, ordinances, orders and decrees applicable to the ownership, testing, in humans or laboratory models, development, manufacture, formulation, packaging, processing, recordkeeping, use, distribution, marketing, labeling, promotion, sale, price reporting, reimbursement, storage, import, export or disposal of any product manufactured or distributed by or for the Company or any of its subsidiaries (“Applicable Laws”), except where the failure to so comply would not, individually or in the aggregate, result in a Material Adverse Effect; (ii) to the knowledge of Company and its subsidiaries, have not, either voluntarily or involuntarily, disclosed to any governmental authority any violations of Applicable Laws, except such as would not, individually or in the aggregate, result in a Material Adverse Effect; (iii) have not received any Food and Drug Administration (“FDA”) Form 483 or any foreign counterpart thereof, warning letter, clinical hold notice or untitled letter from the FDA, any Institutional Review Board (as defined by federal regulation at 21 CFR Section 56.102(g)) or any other governmental authority alleging or asserting noncompliance with any Applicable Laws or any licenses, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), except such as would not, individually or in the aggregate, result in a Material Adverse Effect; (iv) have not received notification of nor have reason to believe that any audits by a governmental authority have resulted in a determination that any of their respective products have been improperly reimbursed, except such audits and determinations as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (v) possess all Authorizations (including, without limitation, exemptions under any Investigational Device Exemption or Investigational New Drug Application, as described at 21 CFR Sections 312 and 812, and approvals of any Institutional Review Board), which are in full force and effect, required for the conduct of their respective businesses (and such Authorizations are valid and in full force and effect) and are not in violation of any term of any such Authorizations, except where the failure to possess such Authorization or the violation of such Authorization would not, individually or in the aggregate, result in a Material Adverse Effect; (vi) have not received written notice of any pending or threatened claim, suit, proceeding, clinical hold, hearing, enforcement, audit, investigation, arbitration, suspension, debarment or exclusion from any governmental authority or Institutional Review Board alleging that any of their respective operations or activities is in violation of any Applicable Laws or Authorizations and the Company has no knowledge or reason to believe that any such governmental authority, Institutional Review Board or other non-governmental authority is considering any such claim, suit, proceeding, clinical hold, hearing, enforcement, audit, investigation, arbitration, suspension, debarment or exclusion except for any such claims, suits, proceedings, clinical holds, hearings, enforcements, audits, investigations, arbitrations, suspensions, debarments or exclusions that would not, individually or in the aggregate, result in a Material Adverse Effect; (vii) have not received written notice that any governmental authority or Institutional Review Board has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and the Company has no knowledge or reason to believe that any such governmental authority is considering such action, except for any such actions that would not, individually or in the aggregate, result in a Material Adverse Effect; (viii) have, or have had on their behalf, filed, declared, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as are required by any Applicable Laws or Authorizations, except where the failure to so file, declare, obtain, maintain or submit would not, individually or in the aggregate, result in a Material Adverse Effect and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (ix) have not, either voluntarily or involuntarily, initiated, conducted or issued, or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, warning, “dear doctor” letter or investigator notice relating to an alleged lack of safety or efficacy of any product or product candidate, any alleged product defect, or violation of any material Applicable Laws or Authorizations and the Company is not aware of any facts that would cause the Company or any of its subsidiaries to initiate any such notice or action and the Company has no knowledge or reason to believe that any governmental authority, Institutional Review Board or other non-governmental authority intends to initiate any such notice or action, except for any such notices or actions that would not, individually or in the aggregate, result in a Material Adverse Effect. Any clinical trials conducted by or on behalf of the Company or any of its subsidiaries that are described in the Registration Statement, the General Disclosure Package or the Prospectus were and, if still pending, are being conducted in compliance in all material respects with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all applicable federal, state, local and foreign laws, rules and regulations, including, but not limited to, the Federal Food, Drug, and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312. Any descriptions of studies, tests and preclinical and clinical trials, including any related results and regulatory status, contained in the Registration Statement, the General Disclosure Package or the Prospectus are, and will be, accurate and complete in all material respects. The Company is not aware of any studies, tests or trials the results of which reasonably call into question in any material respect the clinical trial results described or referred to in the Registration Statement, the General Disclosure Package or the Prospectus. Neither the Company nor any of its subsidiaries has received any written notices or other correspondence from the FDA, an Institutional Review Board or other governmental agency requiring or recommending the termination, suspension or material modification of any clinical trials conducted by, or on behalf of, the Company or any of its subsidiaries or in which the Company or any of its subsidiaries has participated.

  • Regulatory Authority If any regulatory authority having jurisdiction (or any successor boards or agencies), a court of competent jurisdiction or other Governmental Authority with the appropriate jurisdiction (collectively, the ''Regulatory Body'') issues a rule, regulation, law or order that has the effect of cancelling, changing or superseding any term or provision of this Agreement (the ''Regulatory Requirement''), then this Agreement will be deemed modified to the extent necessary to comply with the Regulatory Requirement. Notwithstanding the foregoing, if a Regulatory Body materially modifies the terms and conditions of this Agreement and such modification(s) materially affect the benefits flowing to one or both of the Parties, as determined by either of the Parties within twenty (20) business days of the receipt of the Agreement as materially modified, the Parties agree to attempt in good faith to negotiate an amendment or amendments to this Agreement or take other appropriate action(s) so as to put each Party in effectively the same position in which the Parties would have been had such modification not been made. In the event that, within sixty (60) days or some other time period mutually agreed upon by the Parties after such modification has been made, the Parties are unable to reach agreement as to what, if any, amendments are necessary and fail to take other appropriate action to put each Party in effectively the same position in which the Parties would have been had such modification not been made, then either Party shall have the right to unilaterally terminate this Agreement forthwith.

  • Export Controls Both Parties will adhere to all applicable laws, regulations and rules relating to the export of technical data and will not export or re-export any technical data, any products received from the other Party or the direct product of such technical data to any proscribed country listed in such applicable laws, regulations and rules unless properly authorized.

Time is Money Join Law Insider Premium to draft better contracts faster.